Catalyst Awardee

Project Description

Research and development of new drug loganin for the treatment of depression

Zhang Weiku, PhD | China Japan Friendship Hospital; Xu Jiekun, PhD; He Jun, PhD; Xia Congyuan, PhD
Competition Sponsor: Chinese Academy of Medical Sciences
Awardee Year: 2022

Depression is a kind of affective mental disorder. The main physical symptoms in clinical manifestation are sleep disturbance. The marketed drugs have good antidepressant effects, however they cause easily sleep disorders and headaches, etc. Our team has discovered in recent years that loganin isolated from the traditional Chinese medicine Cornus officinalis has significant antidepressant effect. It has both sleep-promoting and analgesic effects. It was further found that loganin combined with fluoxetine can significantly shorten the onset time of fluoxetine. In addition, the results of toxicity studies in animals showed that loganin has no obvious toxic or side effects. If loganin is successfully developed, it will provide an innovative drug with high safety, definite antidepressant effect, and can improve sleep disorders in patients with depression.


To learn more about this proposal, email

Sign up for updates